OCUP Ocuphire Pharma Inc.

5.19
-0.02  -0%
Previous Close 5.21
Open 5.16
52 Week Low 3.68
52 Week High 13.812
Market Cap $87,694,278
Shares 16,896,778
Float 15,398,882
Enterprise Value $92,162,213
Volume 792,990
Av. Daily Volume 403,027
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Nyxol Eye Drops
Reversal of Mydriasis (RM)
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Nyxol Eye Drops (LYNX-1)
Dim Light or Night Vision Disturbances (DLD)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
APX3330 Oral Pill - (ZETA-1)
Diabetic Retinopathy (DR)/ Macular Edema (DME)
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Nyxol + Low-Dose Pilocarpine Eye Drops (VEGA-1)
Presbyopia
Phase 2
Phase 2
Phase 2 trial met primary endpoint - June 30, 2021.

Latest News

  1. Euro Forums 2021 Virtual Retina Forum on September 8, 2021

    HC Wainwright Virtual 23rd Annual Global Investment Conference on September 13-15, 2021

    Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, 2021

    Cantor Virtual Global Healthcare Conference on September 27-30, 2021

    FARMINGTON HILLS, Mich., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, President and Chief Executive Officer will be presenting corporate overviews at the Euro Forums 2021 Virtual Retina Forum on Wednesday,

    Euro Forums 2021 Virtual Retina Forum on September 8, 2021

    HC Wainwright Virtual 23rd Annual Global Investment Conference on September 13-15, 2021

    Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, 2021

    Cantor Virtual Global Healthcare Conference on September 27-30, 2021

    FARMINGTON HILLS, Mich., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, President and Chief Executive Officer will be presenting corporate overviews at the Euro Forums 2021 Virtual Retina Forum on Wednesday, September 8 as well as participating in 1X1 investor meetings at the HC Wainwright Virtual 23rd Annual Global Investment Conference on Monday, September 13 at 7:00am EDT, the Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21 at 11:35am EDT, and the Cantor Virtual Global Healthcare Conference on Tuesday, September 28 at 10:00am EDT.

    Euro Forums 2021 Virtual Retina Forum on September 8, 2021

      
    Title:Ocuphire Pharma (OCUP)
    Date:Wednesday, September 8, 2021
    Presenter: Mina Sooch, CEO
    Conference Link: https://www.ophthalmology-futures.com/registration/
      
    HC Wainwright Virtual 23rd Annual Global Investment Conference – September 13-15, 2021 

      
    Title:Ocuphire Pharma (OCUP) Company Presentation
    Date:Monday, September 13, 2021
    Time:Available after 7:00 AM EDT and 1X1 Meetings
    Presenter: Mina Sooch, CEO
      
    Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit – September 20-23, 2021
     
    Title: Ocuphire Pharma (OCUP) Company Presentation
    Date:Tuesday, September 21, 2021
    Time:11:35 AM EDT and 1X1 Meetings
    Presenter: Mina Sooch, CEO
    Webcast Link:https://wsw.com/webcast/oppenheimer16/ocup/2797541
      
    Cantor Virtual Global Healthcare Conference – September 27-30, 2021
      
    Title: Ocuphire Pharma (OCUP)
    Date:Tuesday, September 28, 2021
    Time: 10:00 AM EDT and 1X1 Meetings
    Presenter: Mina Sooch, CEO

    If you are interested in arranging a 1X1 meeting request or listening live or to a replay of the company fireside chats with the biotech research analyst, please contact your bank conference representative or ir@ocuphire.com. For more details, please see the Investors and Events section of Ocuphire's corporate website.

    About Ocuphire Pharma

    Ocuphire is a publicly traded (NASDAQ:OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including reversal of pharmacologically-induced mydriasis (RM), presbyopia, and dim light or night vision disturbances (NVD), and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia. Nyxol is also currently in Phase 3 clinical development for NVD. Ocuphire's second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire's completed Phase 2 trials, recently completed Phase 3 registration trial in RM (NCT04620213), recently completed Phase 2 trial in presbyopia (NCT04675151), ongoing Phase 3 registration trial in NVD (NCT04638660), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com.

    Ocuphire Contacts

    Mina Sooch, President & CEO

    Ocuphire Pharma, Inc.

    ir@ocuphire.com

    www.ocuphire.com

    Corey Davis, Ph.D.

    LifeSci Advisors

    cdavis@lifesciadvisors.com



    Primary Logo

    View Full Article Hide Full Article
  2. Continued Momentum in Nyxol® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia

    Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for Best-in-Class Presbyopia Drug Profile in Data Presentations at 2021 ASCRS Meeting

    $24M Cash Balance at Quarter-End Provides Runway Into Late 2022 Allowing Planned NDA Submission for Nyxol in Reversal of Mydriasis Indication

    FARMINGTON HILLS, Mich., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the second quarter of 2021…

    Continued Momentum in Nyxol® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia

    Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for Best-in-Class Presbyopia Drug Profile in Data Presentations at 2021 ASCRS Meeting

    $24M Cash Balance at Quarter-End Provides Runway Into Late 2022 Allowing Planned NDA Submission for Nyxol in Reversal of Mydriasis Indication

    FARMINGTON HILLS, Mich., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the second quarter of 2021 and provided a corporate update.

    "The second quarter of 2021 proved to be highly productive for Ocuphire, with continued success in clinical trials, key pivotal data presentations featured at major medical meetings across both Nyxol and APX3330, and additional IP protection granted for our lead drug candidate Nyxol," said Mina Sooch, MBA, President and CEO of Ocuphire Pharma.

    "Following our first quarter announcement of positive MIRA-2 Phase 3 results of Nyxol for the treatment of reversal of mydriasis (RM), we also announced positive top-line results from our VEGA-1 Phase 2 study, which evaluated Nyxol in combination with low-dose pilocarpine (LDP) for the treatment of presbyopia, the gradual loss of your eyes' ability to focus on nearby objects. In our view, RM and presbyopia both represent attractive and large US and global market opportunities, with each indication having a significant unmet medical need with very few if any pharmaceutical treatment options. Following the recent ASCRS meeting, it is also clear that global pharmaceutical and consumer healthcare companies are aggressively pursuing innovative new medicines, further validating the significant commercial potential for the large presbyopia market. Based upon the success of our VEGA-1 trial, we are highly confident that Nyxol in combination with LDP presents a potentially best-in-class therapeutic solution that can address the needs of the presbyopia patient population."

    "With our balance sheet recently strengthened in the second quarter combined with our capital efficient operations, Ocuphire is well positioned to deliver additional late-stage clinical milestones in 2022 for Nyxol and APX3330 while continuing our global business development efforts."

    Key Anticipated Future Milestones

    • Reversal of Mydriasis (RM): Initiate second Phase 3 (MIRA-3) registration trial and a small pediatric trial (MIRA-4) in the second half of 2021 investigating Nyxol with results expected in early 2022; Planning to file NDA submission with FDA for Nyxol in RM indication in late 2022
    • Presbyopia: Initiate Phase 3 program (VEGA-2/3) in first half of 2022 investigating Nyxol and LDP
    • Night Vision Disturbances: Completion of enrollment expected by year-end 2021 and top-line data expected in early 2022 from Phase 3 (LYNX-1) registration trial investigating Nyxol
    • Diabetic Retinopathy and Diabetic Macular Edema: Completion of enrollment in Phase 2 (ZETA-1) trial investigating APX3330 and top-line data expected in 2022



    Second Quarter and Recent Business Highlights

    Clinical Development

    • In June, the Company announced successful results from the VEGA-1 Phase 2 trial of Nyxol plus low-dose pilocarpine (LDP) for the treatment of presbyopia; the trial met its primary endpoint of 3 lines of near vision improvement and multiple key secondary endpoints such as fast onset of action and durability with statistical significance and a favorable safety profile (including no headaches) 
    • In April, the Company initiated the ZETA-1 Phase 2 clinical trial to evaluate oral APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR)



    Presentations and Publications

    • In July, the Company announced publication in the Journal of Cellular Signaling featuring Ocuphire's novel oral Ref-1 inhibitor APX3330 in Phase 2 trial for the treatment of retinal disease which highlighted the favorable safety profile of APX3330 and its unique anti-angiogenic and anti-inflammatory mechanism of action properties relevant to a broad range of retinal diseases
    • In July at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, Dr. Jay S. Pepose, Medical Advisor and Board Director, presented two papers featuring the positive results Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2)
    • In July, Mina Sooch, CEO, participated in the presbyopia drug therapy panel at the Eyecelerator held on July 22nd and in the Eye on Innovation panel at the Virtual Salon Series held on July 28th
    • In late May, Ocuphire hosted a Key Opinion Leader Event on Nyxol as a potential new treatment option for reversing pharmacologically induced mydriasis, highlighting recent positive Phase 3 results from the MIRA-2 Phase 3 registrational study
    • In May at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, Ocuphire presented data for APX3330 on pre-clinical ocular data and predictive human retina and plasma model data



    Corporate

    • Announced closing of a $15 million registered direct offering and just over $4 million from ATM, extending cash runway into late 2022
    • Appointed Jay S. Pepose, M.D., Ph.D. to the Company's Board of Directors
    • Received two new U.S. patent grants covering Nyxol® including Nyxol plus LDP claims for the treatment of presbyopia through 2039
    • Entered into a license agreement granting Processa Pharmaceuticals (NASDAQ:PCSA) an exclusive license to develop, manufacture and commercialize globally RX-3117 (Rexahn legacy oncology intellectual property), excluding China, Hong Kong, Macau, Republic of Singapore and Taiwan (already licensed to BioSense Global LLC ("BioSense"))
    • Ocuphire (NASDAQ:OCUP) added to the Russell Microcap® Index



    Second Quarter and Year to Date 2021 Financial Highlights

    As of June 30, 2021, the Company had cash and cash equivalents of approximately $24.2 million. Net cash used in operating activities for the three and six months ended June 30, 2021, was $4.3 million and $10.1 million, respectively.

    Collaborations revenue was $0.1 million for the three and six months ended June 30, 2021. Revenue during the periods was derived from the license agreement with BioSense related to certain technology transfers. There was no collaborations revenue recognized during the comparable prior year periods.

    General and administrative expenses for the three and six months ended June 30, 2021, were $3.4 million and $5.1 million, respectively, compared to $0.6 million and $0.9 million, respectively, for the three and six months ended June 30, 2020. The increases from the comparable periods in 2020 were attributable to increased costs primarily in administrative employee headcount, stock-based compensation, insurance, legal and settlement costs, and costs associated with operating as a public company subsequent to the reverse merger.

    Research and development expenses for the three and six months ended June 30, 2021, were $3.8 million and $7.3 million, respectively, compared to $0.7 million and $0.9 million, respectively, for the three and six months ended June 30, 2020. The increases from the comparable periods in 2020 were primarily attributable to four new clinical trials and manufacturing activities for Nyxol and APX3330 as well as regulatory, preclinical, and other development activities.

    There were no acquired in-process research and development expenses in the current six-month period. In the prior year in connection with the sublicense agreement with Apexian for the continued research, development and potential commercialization of APX3330, the Company recorded acquired in-process research and development expenses of $2.1 million during the six-month period ended June 30, 2020.

    The total loss from operations for the three and six months ended June 30, 2021 was $7.1 million and $12.3 million, respectively, compared to $1.3 million and $4.0 million for the three and six months ended June 30, 2020, respectively. This included non-cash stock-based compensation expense of $0.5 million and $1.0 million during the three and six months ended June 30, 2021, respectively, and $0.3 million and $0.4 million during the three and six months ended June 30, 2020, respectively.

    For further details on Ocuphire's financial results, including results for the three and six month periods ended June 30, 2021 refer to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, to be filed with the Securities and Exchange Commission.

    About Ocuphire Pharma

    Ocuphire is a publicly traded (NASDAQ:OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia. Nyxol is also currently in Phase 3 clinical development for NVD. Ocuphire's second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire's completed Phase 2 trials, recently completed Phase 3 registration trial in RM (NCT04620213), recently completed Phase 2 trial in presbyopia (NCT04675151), ongoing Phase 3 registration trial in NVD (NCT04638660), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com.  

    Forward Looking Statements



    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Nyxol plus LDP's potential to be a ‘best-in-class' presbyopia treatment option, the US and global market and commercial potential of Nyxol alone or in combination with LDP, the expected timing of our future clinical trials in RM, NVD, presbyopia, and DR/DME, and the extent of the Company's cash runway. These forward-looking statements are based upon Ocuphire's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) the success and timing of commercialization of any of Ocuphire's product candidates and (x) the maintenance of Ocuphire's intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Ocuphire Contacts

    Mina Sooch, President & CEO 

    Ocuphire Pharma, Inc. 

    ir@ocuphire.com

    www.ocuphire.com

    Corey Davis, Ph.D.

    LifeSci Advisors

    cdavis@lifesciadvisors.com



    Ocuphire Pharma, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share amounts and par value)

      
     As of
     Jun 30,

     Dec 31,

     
     2021  2020 
     (unaudited)

      
    Assets  
    Current assets:  
    Cash and cash equivalents$24,234 $16,399 
    Collaborations receivable 50   
    Prepaids and other assets 956  1,269 
    Total current assets 25,240  17,668 
    Property and equipment, net 12  14 
    Total assets$25,252 $17,682 
       
    Liabilities and stockholders' equity (deficit)  
    Current liabilities:  
    Accounts payable$1,496 $1,214 
    Accrued expenses 1,203  1,971 
    Total current liabilities 2,699  3,185 
    Warrant liabilities   27,964 
    Total liabilities 2,699  31,149 
       
    Commitments and contingencies  
       
    Stockholders' equity (deficit):  
    Preferred stock, par value $0.0001; 10,000,000 shares authorized

      as of June 30, 2021 and December 31, 2020; no shares issued

      and outstanding at June 30, 2021 and December 31, 2020.
        
    Common stock, par value $0.0001; 75,000,000 shares authorized

      as of June 30, 2021 and December 31, 2020; 16,891,855 and

      10,882,495 shares issued and outstanding at June 30, 2021 and

      December 31, 2020, respectively.
     2  1 
    Additional paid-in-capital 101,376  19,207 
    Accumulated deficit (78,825) (32,675)
    Total stockholders' equity (deficit) 22,553  (13,467)
    Total liabilities and stockholders' equity$25,252 $17,682 



    Ocuphire Pharma, Inc.

    Condensed Consolidated Statements of Comprehensive Loss

    (in thousands, except share and per share amounts)

    (unaudited)

      For the Three Months Ended

      For the Six Months Ended

     
      June 30,

      June 30,

     
      2021 2020  2021

     2020

     
    Collaborations revenue $100 $  $100 $ 
                 
    Operating expenses:            
    General and administrative  3,408  551   5,112  942 
    Research and development  3,829  711   7,311  929 
    Acquired in-process research and

    development
             2,126 
    Total operating expenses  7,237  1,262   12,423  3,997 
    Loss from operations  (7,137) (1,262)  (12,323) (3,997)
    Interest expense    (689)    (1,243)
    Fair value change of warrant liability and

    premium conversion derivatives
        (919)  (33,829  (721)
    Gain on note extinguishment    1,260     1,260 
    Other income  1  6   2  9 
    Loss before income taxes  (7,136) (1,604)  (46,150) (4,692)
    Benefit (provision) for income taxes          
    Net loss  (7,136) (1,604)  (46,150) (4,692)
    Other comprehensive loss, net of tax          
    Comprehensive loss $(7,136)$(1,604) $(46,150)$(4,692)
    Net loss per share:             
    Basic and diluted $(0.52)$(0.43) $(3.76)$(1.29)
    Number of shares used in per share

    calculations:
                
    Basic and diluted  13,608,596  3,743,907   12,273,541  3,645,948 


    Primary Logo

    View Full Article Hide Full Article
  3. Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10-12, 2021

    HC Wainwright Ophthalmology Virtual Conference on August 17, 2021

    FARMINGTON HILLS, Mich., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that Mina Sooch, President and Chief Executive Officer will be participating in a fireside chat on Thursday, August 12, 2021, and one-on-one investor meetings throughout the virtual Canaccord Genuity 41st Annual Growth Conference. On Tuesday August 17, 2021, Ms. Sooch will also be presenting a corporate overview highlighting…

    Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10-12, 2021

    HC Wainwright Ophthalmology Virtual Conference on August 17, 2021

    FARMINGTON HILLS, Mich., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that Mina Sooch, President and Chief Executive Officer will be participating in a fireside chat on Thursday, August 12, 2021, and one-on-one investor meetings throughout the virtual Canaccord Genuity 41st Annual Growth Conference. On Tuesday August 17, 2021, Ms. Sooch will also be presenting a corporate overview highlighting recent positive Phase 2 data in the Nyxol program, presbyopia, participating in an innovative retina therapies panel given Ocuphire's APX3330 oral candidate, and available for one-on-one investor meetings at the HC Wainwright Ophthalmology Virtual Conference.

    Canaccord Genuity 41st Annual Growth Conference (Virtual) – August 10-12, 2021
        
    Title:   Ocuphire Pharma (OCUP) Fireside Chat
    Date:    Thursday, August 12th, 2021
    Time:    3:30-3:55 PM EST
    Presenter:    Mina Sooch, CEO
    Track:    4
    Live Webcast:    Link Here
        
    HC Wainwright Ophthalmology Virtual Conference – August 17, 2021
        
    Title:    Ocuphire Pharma (OCUP) Company Presentation
    Date:    Tuesday, August 17th, 2021
    Time:    Available after 7:00 AM EST
    Presenter:    Mina Sooch, CEO
    Registration Link:    Link Here
        
    Panel Title:    Vision Repair Beyond Traditional Anti-VEGF Therapy - What Does the

    Future Hold?
    Date:    Tuesday, August 17th, 2021
    Time:    12:00-1:00 PM EST
    Presenter:    Ocuphire, Mina Sooch, CEO (alongside four leading companies)
    Live Webcast:    Link Here

    If you are interested in arranging a one-on-one meeting request, please contact your bank conference representative or ir@ocuphire.com. For more details, please see the Investors and Events section of Ocuphire's corporate website.

    About Ocuphire Pharma

    Ocuphire is a publicly traded (NASDAQ:OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia. Nyxol is also currently in Phase 3 clinical development for NVD. Ocuphire's second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire's completed Phase 2 trials, recently completed Phase 3 registration trial in RM (NCT04620213), recently completed Phase 2 trial in presbyopia (NCT04675151), ongoing Phase 3 registration trial in NVD (NCT04638660), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com

    Forward Looking Statements



    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Ocuphire's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) the success and timing of commercialization of any of Ocuphire's product candidates and (x) the maintenance of Ocuphire's intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Ocuphire Contacts

    Mina Sooch, President & CEO 

    Ocuphire Pharma, Inc. 

    ir@ocuphire.com

    www.ocuphire.com 

    Corey Davis, Ph.D.

    LifeSci Advisors

    cdavis@lifesciadvisors.com



    Primary Logo

    View Full Article Hide Full Article
  4. Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases

    Phase 2 Data from ZETA-1 Trial in Diabetic Retinopathy Expected in 2022

    FARMINGTON HILLS, Mich., July 22, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled "APE1/Ref-1 as a Novel Target

    Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases

    Phase 2 Data from ZETA-1 Trial in Diabetic Retinopathy Expected in 2022

    FARMINGTON HILLS, Mich., July 22, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled "APE1/Ref-1 as a Novel Target for Retinal Disease".

    The Journal of Cellular Signaling is an open-access peer reviewed journal which features articles on latest research findings and perspectives on cellular and molecular signaling – an essential process that orchestrates and integrates various biological functions through multiple signaling cascades and effector molecules. The article can be accessed online at the following link: Welcome to Scientific Archives | APE1/Ref-1 as a Novel Target for Retinal Diseases.

    "We have now published over 21 peer-reviewed articles on APX3330 and over 70 articles on the APE1/Ref-1 target in various journals, with 5 publications specifically related to retinal disease," said Mark R. Kelley, PhD, Professor in the Department of Pediatrics and Glick Eye Center at Indiana University School of Medicine and member of Ocuphire's Medical Advisory Board. "This published commentary article discusses the comprehensive data on both Ref-1 as a novel retina target as well as our oral inhibitor, APX3330, predicted to reach human retinal concentrations several-fold greater than the dose required to show efficacy in mice. APX3330 simultaneously blocks key pathways involved in angiogenesis and inflammation processes, thereby conferring protection to the retina. APX3330 represents the Ref-1 program's lead compound, with pipeline candidates APX2009 and APX2014 that could be formulated for intravitreal sustained release delivery."

    Highlights from the APE1/Ref-1 Review Article:

    • Ref-1 protein regulates multiple transcription factors regulating inflammation and angiogenesis.
    • As a Ref-1 inhibitor, APX3330 decreases both abnormal angiogenesis and inflammation by blocking activation of HIF-1a, which then leads to reduced VEGF signaling and lower production of pro-inflammatory cytokines such as NF-kB, TNF-alpha, and STAT3.
    • At the 300 mg oral twice per day dose being used in the ongoing Phase 2 clinical trial in patients with diabetic retinopathy (DR), APX3330 is expected to reach several-fold higher retinal Cmax, and many-fold concentrations above 15.4 ug/ml retinal AUC, than the efficacious dose of oral gavage 25 mg/kg twice per day given to mice in the L-CNV model of retinal disease.
    • In five Phase 2 studies involving over 300 patients, APX3330 given oral (systemically) was well tolerated with no significant safety issues identified. No AE was observed in ≥ 5% of patients treated with APX3330. Mild rash and mild diarrhea were observed in 1% of APX3330 treated patients and were thought to be possibly drug-related.
    • Ocuphire is presently recruiting for ZETA-1 Phase 2 clinical trial, which will enroll subjects across 20 U.S. sites with the primary endpoint of the percentage of subjects with >2-step improvement on the Diabetic Retinopathy Severity Scale score.

    The primary endpoint for the ZETA-1 trial is the Early Treatment Diabetic Retinopathy Score (ETDRS) diabetic retinopathy severity score (DRSS). This score is based on vascular abnormalities in retinal photographs, and a 2-step or more improvement in this score is the accepted regulatory endpoint for the treatment of DR. In the PANORAMA study which examined the effect of the anti-VEGF drug EYLEA® on DRSS, this primary endpoint was met with significantly more patients responding to treatment compared to placebo after 24 weeks of 2mg dosing intravitreal every 16 weeks. In the mouse L-CNV model, the efficacy of oral APX3330 was similar to EYLEA intravitreal injections. Taken together with the other safety, PK, and preclinical data, this provides a strong rationale for pursuing diabetic retinopathy in the ZETA-1 trial. Visual function and central retinal thickness will also be measured given the expected efficacy in treatment of diabetic macular edema (DME).

    "With its dual mechanism of action targeting pathogenic inflammation downstream to Ref-1, we believe APX3330 could represent an important new therapeutic approach in addressing a number of ocular conditions, including as a single agent for diabetic retinopathy and as an adjunctive therapy to anti-VEGF in diabetic macular edema, wet age-related macular degeneration, and other retinal diseases," said Mina Sooch, MBA, President and CEO of Ocuphire Pharma. "We are fortunate to build on the past 11 Phase 1 and 2 clinical trials studying inflammation in liver diseases by Eisai and angiogenesis in oncology by Apexian. As our clinical program surrounding Ref-1 inhibition continues to mature, we expect APX3330 to generate more attention ahead of our Phase 2 data readout in diabetic retinopathy anticipated next year."

    The progressive pathogenesis of retinal and choroidal disease often involves vascular leakage, retinal ischemia, and the release of vasoproliferative growth factors and inflammatory mediators. Earlier treatment options to prevent or delay irreversible vision loss for patients with diabetic eye disease are critical. Although biologic therapies such as Eylea (which are injections directly into the eye) have been approved in the field, the invasive nature of treatment leads to a reluctance by physicians to adopt bi-monthly chronic injection regimens during the early stages of disease progression. Today, diabetic retinopathy remains closely monitored by retinal specialists but largely untreated. An alternative (oral) treatment modality presents immense potential to be used as monotherapy for non-proliferative or early proliferative stages of diabetic retinopathy.

    "As an oral tablet with a favorable safety profile demonstrated in the early clinical trials, APX3330 could offer a convenient solution for a large and growing global population of diabetes-related retinal diseases," said Dr. Peter Kaiser, Professor of Ophthalmology at the Cole Eye Institute, Cleveland Clinic. "More importantly, APX3330 has the potential to reduce the burden of intravitreal injections on the patients."

    About Diabetic Retinopathy

    Diabetes is the leading cause of blindness among adults aged 20 – 74. In the United States alone, over 7 million patients suffer from diabetic retinopathy (DR), a complication of diabetes in which chronically elevated blood sugar levels cause damage to blood vessels in the retina. An additional 750,000 patients suffer from diabetic macular edema (DME), one of the most common complications of diabetic retinopathy where the macula swells from fluid leaked from damaged blood vessels. The disease progression of both DR and DME involves abnormal vessel proliferation and inflammation. Thus, current approved treatments for DR and DME encompass an over $10 billion global market and involve administering anti-VEGF injections (such as EYLEA® by Regeneron, Lucentis® by Genentech, and Avastin® by Genentech) to decrease vessel formation or steroids (such as OZURDEX® by Abbvie/Allergan) to decrease inflammation into eyes with advanced retinal disease. ZETA-1 is investigating the potential of APX3330 to offer an innovative and conveniently administered oral treatment for diabetic retinopathy that addresses both of these disease pathways.

    About Ocuphire Pharma

    Ocuphire is a publicly traded (NASDAQ:OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia. Nyxol is also currently in Phase 3 clinical development for NVD. Ocuphire's second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire's completed Phase 2 trials, recently completed Phase 3 registration trial in RM (NCT04620213), recently completed Phase 2 trial in presbyopia (NCT04675151), ongoing Phase 3 registration trial in NVD (NCT04638660), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com

    Forward Looking Statements



    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the expected timing of the Phase 2 ZETA-1 clinical trial in diabetic retinopathy, the potential formulation of APX2009 and APX2014, and the ability of APX3330 to represent an important new therapeutic approach in addressing a number of ocular conditions. These forward-looking statements are based upon Ocuphire's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) the success and timing of commercialization of any of Ocuphire's product candidates and (x) the maintenance of Ocuphire's intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Ocuphire Contacts

    Mina Sooch, President & CEO 

    Ocuphire Pharma, Inc. 

    ir@ocuphire.com

    www.ocuphire.com 

    Corey Davis, Ph.D.

    LifeSci Advisors

    cdavis@lifesciadvisors.com



    Primary Logo

    View Full Article Hide Full Article
  5. Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas

    Ocuphire Presenting Nyxol® + Low Dose Pilocarpine Phase 2 Data in the Presbyopia Industry Panel at Eyecelerator@ASCRS in Las Vegas

    Ocuphire to Highlight Novel Refractive and Retinal Approaches in Ophthalmology at Eye on Innovation Demy-Colton Virtual Salon Series

    FARMINGTON HILLS, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that Dr. Jay S. Pepose, Medical Advisor and Board Director…

    Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas

    Ocuphire Presenting Nyxol® + Low Dose Pilocarpine Phase 2 Data in the Presbyopia Industry Panel at Eyecelerator@ASCRS in Las Vegas

    Ocuphire to Highlight Novel Refractive and Retinal Approaches in Ophthalmology at Eye on Innovation Demy-Colton Virtual Salon Series

    FARMINGTON HILLS, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that Dr. Jay S. Pepose, Medical Advisor and Board Director, will be presenting two papers on presbyopia and reversal of mydriasis (RM) at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held on July 23-27, 2021 and that Mina Sooch, CEO and Board Director, will be participating in the presbyopia industry panel at the Eyecelerator on July 22, 2021 and in the Eye on Innovation panel at the Virtual Salon Series on July 28, 2021.

    "We are excited to share more broadly the results from our two Nyxol® programs in reversal of mydriasis and presbyopia at these global industry forums with physicians, strategic partners, and investors," said Mina Sooch, MBA, President and CEO of Ocuphire Pharma. "We remain on track with our plans for the potential NDA submission for Nyxol in RM in late 2022. With respect to our presbyopia program, we believe the recently announced favorable safety profile and positive efficacy data from our Phase 2 VEGA-1 study position Nyxol + low dose pilocarpine to be a potentially best-in-class product for this extremely large age-related patient population. In the Presbyopia New Treatments session at ASCRS, Ocuphire will present new and differentiated data alongside the most advanced program AGN-190584 by Abbvie/Allergan."

    Eyecelerator @ASCRS  
      
    Panel Title:Presbyopia: Everybody gets it but... can it be fixed?  
    Date:Thursday, July 22nd, 2021  
    Location:Mandalay Bay South Convention Center, Las Vegas  
    Time:2:15-2:55 pm PDT  
    Presenter:Ocuphire, Mina Sooch, CEO (together with five leading companies in late-stage clinical development of eye drops for presbyopia)  
    Conference Link:https://www.eyecelerator.com/
     
    2021 ASCRS Annual Meeting
      
    Session:SPS-204 - Presbyopia Correcting IOL Comparisons, New Treatments and Studies
    Title:Phase 2 Clinical Trial to Evaluate the Efficacy of Phentolamine Ophthalmic Solution and Low-Dose Pilocarpine for the Treatment of Presbyopia
    Date:Sunday, July 25th, 2021
    Time:8:45 am – 8:50 am PDT
    Location:Mandalay Bay Convention Center, Las Vegas

    MBCR – Level 2, Lagoon EF

    Presenter:Jay S. Pepose, MD, PhD, ABO
      
    Session:SPS-316 - Corneal Diagnostic Studies
    Title:Phase 3 Clinical Trial to Evaluate the Efficacy of Phentolamine Ophthalmic Solution on the Reversal of Pharmacologically Induced Mydriasis
    Date:Monday, July 26th, 2021
    Time:4:25 pm – 4:30 pm PDT
    Location:Mandalay Bay Convention Center, Las Vegas

    MBCR – Level 2, Lagoon F

    Presenter:Jay S. Pepose, MD, PhD, ABO
      
    Demy-Colton Virtual Salon Series  
     
    Title:Ophthalmic Drug Delivery: Eye on Innovation  
    Date:Wednesday, July 28th, 2021  
    Time:11:00 am – 12:15 pm ET  
    Presenter:Mina Sooch, CEO  
    Live Discussion:Registration Link

    About Ocuphire Pharma

    Ocuphire is a publicly traded (NASDAQ:OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company's lead product candidate, Nyxol® (0.75% phentolamine ophthalmic solution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 9 clinical trials including the recently completed Phase 3 trial in RM and Phase 2 trial in presbyopia. Ocuphire reported positive topline data in March 2021 for MIRA-2, a Phase 3 FDA registration study for treatment of RM. Ocuphire also reported positive top-line data in June 2021 for VEGA-1, a Phase 2 trial for the treatment of presbyopia. Nyxol is also currently in Phase 3 clinical development for NVD. Ocuphire's second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Phase 1 and 2 trials. APX3330 is currently enrolling subjects in a Phase 2 clinical trial in subjects with DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire's completed Phase 2 trials, recently completed Phase 3 registration trial in RM (NCT04620213), recently completed Phase 2 trial in presbyopia (NCT04675151), ongoing Phase 3 registration trial in NVD (NCT04638660), and Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com

    Forward Looking Statements



    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning a potential Phase 3 trial in presbyopia, Nyxol + LDP's potential to be a ‘best in class' presbyopia treatment option, and the market and commercial potential of Nyxol + LDP. These forward-looking statements are based upon Ocuphire's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, (ix) the success and timing of commercialization of any of Ocuphire's product candidates and (x) the maintenance of Ocuphire's intellectual property rights. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Ocuphire Contacts

    Mina Sooch, President & CEO

    Ocuphire Pharma, Inc.

    ir@ocuphire.com

    www.ocuphire.com

    Corey Davis, Ph.D.

    LifeSci Advisors

    cdavis@lifesciadvisors.com



    Primary Logo

    View Full Article Hide Full Article
View All Ocuphire Pharma Inc. News